| 词条 | Gevokizumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458274816 | type = mab | image = | alt = | mab_type = mab | source = zu/o | target = Interleukin 1β | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1129435-60-4 | ATC_prefix = None | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = QX3JU54GYQ | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D09911 | C=6442 | H=9962 | N=1710 | O=2010 | S=52 | molecular_weight = 145.2 kg/mol | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = None }} Gevokizumab is a potent monoclonal antibody, developed by XOMA Corporation, with unique allosteric modulating properties and the potential to treat patients with a wide variety of diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. On August 25, 2017, XOMA Corporation licensed the global commercial rights to gevokizumab to Novartis. Under the license agreement, Novartis will have worldwide rights to gevokizumab, and will be solely responsible for the development and commercialization of antibodies and products containing antibodies arising from gevokizumab. XOMA received an approximately $16 million upfront payment, and Novartis repaid in its entirety the approximately €12 million of debt owed by XOMA to Les Laboratoires Servier. XOMA is eligible to receive up to $438 million in development, regulatory and commercial milestones plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab. Novartis is exploring options for Gevokizumab development as part of its pharmaceutical portfolio. References{{Monoclonals for immune system}}{{Interleukin receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。